Early recognition of poor prognosis in Guillain-Barré syndrome
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Guillain-Barré syndrome (GBS) has a highly diverse clinical course and outcome, yet patients are treated with a standard therapy. Patients with poor prognosis may benefit from additional treatment, provided they can be identified early, when nerve degeneration is potentially reversible and treatment is most effective. We developed a clinical prognostic model for early prediction of outcome in GBS, applicable for clinical practice and future therapeutic trials.
Methods: Data collected prospectively from a derivation cohort of 397 patients with GBS were used to identify risk factors of being unable to walk at 4 weeks, 3 months, and 6 months. Potential predictors of poor outcome (unable to walk unaided) were considered in univariable and multivariable logistic regression models. The clinical model was based on the multivariable logistic regression coefficients of selected predictors and externally validated in an independent cohort of 158 patients with GBS.
Results: High age, preceding diarrhea, and low Medical Research Council sumscore at hospital admission and at 1 week were independently associated with being unable to walk at 4 weeks, 3 months, and 6 months (all p 0.05–0.001). The model can be used at hospital admission and at day 7 of admission, the latter having a better predictive ability for the 3 endpoints; the area under the receiver operating characteristic curve (AUC) is 0.84–0.87 and at admission the AUC is 0.73–0.77. The model proved to be valid in the validation cohort.
Conclusions: A clinical prediction model applicable early in the course of disease accurately predicts the first 6 months outcome in GBS.
Footnotes
-
- AUC
- area under the receiver operating characteristic curve
- CMV
- cytomegalovirus
- EGOS
- Erasmus GBS Outcome Score
- GBS
- Guillain-Barré syndrome
- IVIg
- IV immunoglobulin
- LR
- likelihood ratio
- mEGOS
- modified Erasmus GBS Outcome Score
- MP
- methylprednisolone
- MRC
- Medical Research Counsel
- OR
- odds ratio
- PE
- plasma exchange
-
Supplemental data at www.neurology.org
- Received September 9, 2010.
- Accepted December 3, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Axonal variant of Guillain-Barré syndrome associated with Campylobacter infection in BangladeshZ. Islam, B. C. Jacobs, A. van Belkum et al.Neurology, February 15, 2010 -
Article
Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni InfectionAna P. Ramos, Sonja E. Leonhard, Susan K. Halstead et al.Neurology: Neuroimmunology & Neuroinflammation, February 05, 2021 -
Articles
Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathiesK. Kimoto, M. Koga, M. Odaka et al.Neurology, November 27, 2006 -
Articles
Antecedent infections in Fisher syndromeA common pathogenesis of molecular mimicryM. Koga, M. Gilbert, J. Li et al.Neurology, May 09, 2005